These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 8045754

  • 21. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A, Imbach P, Pfenninger E, Stocker F, Töndury P, Wagner HP, Weber J, Zuppinger K.
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [Abstract] [Full Text] [Related]

  • 22. Self-reported level of and factors influencing the compliance to desferrioxamine therapy in multitransfused thalassaemias.
    Lee WS, Toh TH, Chai PF, Soo TL.
    J Paediatr Child Health; 2011 Aug; 47(8):535-40. PubMed ID: 21392144
    [Abstract] [Full Text] [Related]

  • 23. [Beta-thalassemia in Germany. Results of cooperative beta-thalassemia study].
    Cario H, Stahnke K, Kohne E.
    Klin Padiatr; 1999 Aug; 211(6):431-7. PubMed ID: 10592921
    [Abstract] [Full Text] [Related]

  • 24. [Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children].
    Bachelot C, Plantaz D.
    Pediatrie; 1990 Aug; 45(9):619-23. PubMed ID: 2175425
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Chelating therapy in beta-thalassemia].
    Musumeci S, Romeo MA, Di Gregorio F, Schiliró G, Russo G.
    Pediatr Med Chir; 1982 Aug; 4(1-2):55-9. PubMed ID: 7111040
    [Abstract] [Full Text] [Related]

  • 27. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C, Franchini M, Gandini G, Vassanelli A, De Gironcoli M, Aprili G.
    Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Continuous subcutaneous deferoxamine infusions in thalassemia major. Improvement in glucose tolerance].
    Krüger N, Stubbe P, Tillmann W, Schröter W.
    Dtsch Med Wochenschr; 1986 May 02; 111(18):698-701. PubMed ID: 3486106
    [Abstract] [Full Text] [Related]

  • 30. Management of iron overload in the pediatric patient.
    Cohen A.
    Hematol Oncol Clin North Am; 1987 Sep 02; 1(3):521-44. PubMed ID: 3329185
    [Abstract] [Full Text] [Related]

  • 31. Morbidities and mortality in transfusion-dependent Beta-thalassemia patients (single-center experience).
    Mokhtar GM, Gadallah M, El Sherif NH, Ali HT.
    Pediatr Hematol Oncol; 2013 Mar 02; 30(2):93-103. PubMed ID: 23301991
    [Abstract] [Full Text] [Related]

  • 32. [Ocular findings in Desferal therapy].
    Dennerlein JA, Lang GE, Stahnke K, Kleihauer E, Lang GK.
    Ophthalmologe; 1995 Feb 02; 92(1):38-42. PubMed ID: 7719074
    [Abstract] [Full Text] [Related]

  • 33. Beta-thalassaemia--the Johannesburg experience.
    Poole JE, Cohn RJ, Roode H, Spector I.
    S Afr Med J; 1989 Apr 15; 75(8):367-70. PubMed ID: 2652340
    [Abstract] [Full Text] [Related]

  • 34. [Beta-pancreatic function in subjects with thalassemia. A 4-year follow-up].
    Zanini R, Briante G, Cantone P, Sticca M, Grasso U.
    Pediatr Med Chir; 1985 Apr 15; 7(5):749-53. PubMed ID: 3915549
    [Abstract] [Full Text] [Related]

  • 35. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia.
    Davis BA, Porter JB.
    Blood; 2000 Feb 15; 95(4):1229-36. PubMed ID: 10666195
    [Abstract] [Full Text] [Related]

  • 36. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.
    Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri NF.
    Int J Hematol; 1991 Oct 15; 54(5):371-5. PubMed ID: 1756248
    [Abstract] [Full Text] [Related]

  • 37. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I, Hatzidimitriou-Papazacharia K, Spiliotopoulou J, Tsagarakis N, Digenopoulou E.
    Birth Defects Orig Artic Ser; 1988 Oct 15; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract] [Full Text] [Related]

  • 38. Compliance of deferoxamine injection in beta-thalassaemia major patients in Iran.
    Rashid M, Karimi M.
    Transfus Med; 2012 Apr 15; 22(2):104-7. PubMed ID: 22212011
    [Abstract] [Full Text] [Related]

  • 39. Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis.
    Cianciulli P, Sorrentino F, Forte L, Palombi M, Papa G, Meloni C, Taccone Gallucci M, Casciani CU.
    Haematologica; 1992 Apr 15; 77(6):514-5. PubMed ID: 1289188
    [Abstract] [Full Text] [Related]

  • 40. Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine.
    Olivieri NF, Berriman AM, Tyler BJ, Davis SA, Francombe WH, Liu PP.
    Am J Hematol; 1992 Sep 15; 41(1):61-3. PubMed ID: 1503101
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.